Sunifiram (DM-235) is a piperazine derived ampakine-like drug which has nootropic effects in animal studies with significantly higher potency than piracetam. A number of related compounds are known, including unifiram (DM-232).

Mechanism of Action:

Sunifiram acts as an agonist of AMPA receptors.

Sunifiram aids in the release of acetylcholine in the cerebral cortex.

Benifits:

The majority of studies that have been conducted on Sunifiram so far point to its anti-amnesic effect, and its implications in the treatment of Alzheimer’s, in comparison to other drugs in the Racetam category. In comparison, with Piracetam being the most well-known of the Racetams, Sunifiram is noted to be roughly 1000 time more potent than Piracetam (by weight).

Researchers concluded that Sunifiram appears to be highly-effective at preventing cognitive decline, but were unable to determine how Sunifiram may effect otherwise healthy individuals, due to the nature of the study.

Another study used olfactory bulbectomized mice to test what effect Sunifiram has on both memory impairment and depression.